Cargando…
Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies
BH3 mimetics are novel targeted drugs with remarkable specificity, potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to incr...
Autores principales: | Al-Zebeeby, Aoula, Vogler, Meike, Milani, Mateus, Richards, Caitlin, Alotibi, Ahoud, Greaves, Georgia, Dyer, Martin J.S., Cohen, Gerald M., Varadarajan, Shankar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518917/ https://www.ncbi.nlm.nih.gov/pubmed/30467206 http://dx.doi.org/10.3324/haematol.2018.204701 |
Ejemplares similares
-
Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
por: Carter, Rachel J., et al.
Publicado: (2019) -
DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis
por: Milani, Mateus, et al.
Publicado: (2019) -
DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
por: Milani, Mateus, et al.
Publicado: (2017) -
Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023) -
BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)